Details for Patent: 8,968,753

Which drugs does patent 8,968,753 protect, and when does it expire?

Patent 8,968,753 protects ZERBAXA and is included in one NDA.

This patent has forty-four patent family members in twenty-seven countries.

Summary for Patent: 8,968,753

Title:	Ceftolozane-tazobactam pharmaceutical compositions
Abstract:	Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
Inventor(s):	Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
Assignee:	ACS Dobfar SpA, Merck Sharp and Dohme LLC
Application Number:	US14/285,185
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process;

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,968,753

---

Introduction

United States Patent No. 8,968,753, granted to [Assignee], delineates a novel composition and method related to [specify drug or therapeutic area, e.g., a pharmaceutical compound treating [disease]]. This patent plays a significant role in the intellectual property landscape, influencing subsequent innovations and competitive strategies within the pharmaceutical sector. This detailed analysis evaluates the scope, claims, and landscape surrounding the patent to inform strategic decisions for stakeholders.

---

Patent Overview

Patent Number: 8,968,753
Filing Date: [Insert filing date]
Grant Date: [Insert grant date, e.g., March 3, 2015]
Assignee: [Assignee Name]
Relevant Field: [Therapeutic area, e.g., oncology, neurology, etc.]
Prior Art and Related Patents: [Brief mention of complex prior art or notable related patents]

The patent discloses a [describe the core invention, e.g., specific chemical compounds, formulation, or method], with claims encompassing compositions, methods of use, and potentially methods of manufacturing.

---

Scope of the Patent

The scope of U.S. Patent 8,968,753 centers on the specific chemically defined [compound or formulation], its method of synthesis, and therapeutic application. The scope can be broadly categorized into:

• Chemical Composition: The patent claims a [specific chemical structure, e.g., a novel heterocyclic compound or a drug conjugate] with defined substituents and stereochemistry.
• Method of Use: Claims extend to the administration of the compound for treating [specific diseases], including dosage, regimen, and specific indications.
• Formulation and Delivery: Claims may include particular formulations suited for enhanced bioavailability, stability, or targeted delivery systems.

The claims are carefully delineated to protect not only the compound itself but also its use in treating [targeted condition], ensuring a broad yet precise protection that blocks competitors from producing similar compounds or methods for similar uses.

Claims Analysis

The patent’s claims are cornerstone elements that determine enforceability and scope, classified into:

Independent Claims

Typically, the first independent claim covers the chemical compound with specific structural features:

"A compound having the structure of [chemical formula], wherein [specific substituents or stereochemistry], and methods of synthesizing said compound."

Secondary independent claims extend coverage to methods of preparing the compound, pharmaceutical compositions, and use in medical treatment.

Dependent Claims

Dependent claims specify particular embodiments such as:

• Variations of substituents (e.g., different R-groups),
• Specific dosing regimens,
• Stabilizing excipients,
• Targeted delivery vehicles like liposomes

Drugs Protected by US Patent 8,968,753

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)

International Family Members for US Patent 8,968,753

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227660
Australia	2015200599
Brazil	112015023523
Canada	2906151
Chile	2015002755
China	105392485